BC Extra | Mar 8, 2017
Company News

Management tracks

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said Chairman Leonard Bell will retire from its board, effective May 10. Fosun Kite Biotechnology Co. Ltd., a JV between Kite Pharma Inc. (NASDAQ:KITE) and Shanghai Fosun Pharmaceutical Group Co. Ltd....
BC Extra | Mar 2, 2017
Company News

Management tracks

Inflammatory and neurological disease company Forward Pharma A/S (NASDAQ:FWP) promoted Claus Svendsen to CEO from EVP. He replaces Peder Andersen, who will remain Forward's COO until Sept. 1. The WuXi NextCODE genomics unit of New...
BC Week In Review | Sep 8, 2014
Company News

Lundbeck sales and marketing update

H. Lundbeck launched Northera droxidopa in the U.S. to treat symptomatic neurogenic orthostatic hypotension (NOH). The wholesale acquisition cost for a package containing 90 capsules is $1,409 for the 100 mg capsules; $2,818 for 200...
BC Week In Review | Jun 30, 2014
Company News

Lundbeck, Chelsea Therapeutics deal

H. Lundbeck completed its acquisition of Chelsea for up to $7.94 per share, or about $626.8 million. Chelsea shareholders will receive $6.44 per share in cash, or about $508.3 million, and a contingent value right...
BioCentury | Jun 16, 2014
Finance

Biotech rating scheme

Claravant Analytics LLC is aiming to change the biotech investment ecosystem by leveling the playing field for public investors that don't have access to confidential information. The firm plans to serve as a third-party intermediary...
BC Week In Review | Jun 2, 2014
Company News

Chelsea Therapeutics, Lundbeck deal

H. Lundbeck began its tender offer to acquire Chelsea for up to $7.94 per share, or about $626.8 million. Chelsea shareholders will receive $6.44 per share in cash, or about $508.3 million, and a contingent...
BC Week In Review | May 12, 2014
Company News

Chelsea Therapeutics, Lundbeck deal

Lundbeck will acquire Chelsea in a deal worth up to $7.94 per share, or about $626.8 million based on 78.9 million Chelsea shares outstanding as of May 2. Chelsea shareholders will receive $6.44 per share...
BioCentury | May 12, 2014
Finance

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
BioCentury | May 12, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) slipped $2.25 to $152.87 last week after FDA granted full approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). The agency granted accelerated approval for Soliris for...
BC Extra | May 9, 2014
Top Story

Lundbeck to acquire Chelsea

H. Lundbeck A/S (CSE:LUN) will acquire Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) in a deal worth up to $7.94 per share, or about $626.8 million based on 78.9 million Chelsea shares outstanding as of May 2....
Items per page:
1 - 10 of 236
BC Extra | Mar 8, 2017
Company News

Management tracks

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said Chairman Leonard Bell will retire from its board, effective May 10. Fosun Kite Biotechnology Co. Ltd., a JV between Kite Pharma Inc. (NASDAQ:KITE) and Shanghai Fosun Pharmaceutical Group Co. Ltd....
BC Extra | Mar 2, 2017
Company News

Management tracks

Inflammatory and neurological disease company Forward Pharma A/S (NASDAQ:FWP) promoted Claus Svendsen to CEO from EVP. He replaces Peder Andersen, who will remain Forward's COO until Sept. 1. The WuXi NextCODE genomics unit of New...
BC Week In Review | Sep 8, 2014
Company News

Lundbeck sales and marketing update

H. Lundbeck launched Northera droxidopa in the U.S. to treat symptomatic neurogenic orthostatic hypotension (NOH). The wholesale acquisition cost for a package containing 90 capsules is $1,409 for the 100 mg capsules; $2,818 for 200...
BC Week In Review | Jun 30, 2014
Company News

Lundbeck, Chelsea Therapeutics deal

H. Lundbeck completed its acquisition of Chelsea for up to $7.94 per share, or about $626.8 million. Chelsea shareholders will receive $6.44 per share in cash, or about $508.3 million, and a contingent value right...
BioCentury | Jun 16, 2014
Finance

Biotech rating scheme

Claravant Analytics LLC is aiming to change the biotech investment ecosystem by leveling the playing field for public investors that don't have access to confidential information. The firm plans to serve as a third-party intermediary...
BC Week In Review | Jun 2, 2014
Company News

Chelsea Therapeutics, Lundbeck deal

H. Lundbeck began its tender offer to acquire Chelsea for up to $7.94 per share, or about $626.8 million. Chelsea shareholders will receive $6.44 per share in cash, or about $508.3 million, and a contingent...
BC Week In Review | May 12, 2014
Company News

Chelsea Therapeutics, Lundbeck deal

Lundbeck will acquire Chelsea in a deal worth up to $7.94 per share, or about $626.8 million based on 78.9 million Chelsea shares outstanding as of May 2. Chelsea shareholders will receive $6.44 per share...
BioCentury | May 12, 2014
Finance

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
BioCentury | May 12, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) slipped $2.25 to $152.87 last week after FDA granted full approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). The agency granted accelerated approval for Soliris for...
BC Extra | May 9, 2014
Top Story

Lundbeck to acquire Chelsea

H. Lundbeck A/S (CSE:LUN) will acquire Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) in a deal worth up to $7.94 per share, or about $626.8 million based on 78.9 million Chelsea shares outstanding as of May 2....
Items per page:
1 - 10 of 236